Cost‐Effectiveness of LDL‐C Lowering With Evolocumab in Patients With High Cardiovascular Risk in the United States

Randomized trials have shown marked reductions in low‐density lipoprotein cholesterol (LDL‐C), a risk factor for cardiovascular disease (CVD), when evolocumab is administered. We hypothesized that evolocumab added to standard of care (SOC) vs SOC alone is cost‐effective in the treatment of patients...

Descripción completa

Detalles Bibliográficos
Autores principales: Gandra, Shravanthi R., Villa, Guillermo, Fonarow, Gregg C., Lothgren, Mickael, Lindgren, Peter, Somaratne, Ransi, van Hout, Ben
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2016
Materias:
Quality and Outcomes
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074319/
https://www.ncbi.nlm.nih.gov/pubmed/27092712
http://dx.doi.org/10.1002/clc.22535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074319/
https://www.ncbi.nlm.nih.gov/pubmed/27092712
http://dx.doi.org/10.1002/clc.22535

Ejemplares similares